US medical devices industry saw a drop of 2.30% in overall deal activity during June 2021, when compared with the last 12-month average, led by GIC, Hellman & Friedman, The Blackstone Group and The Carlyle Group’s $34bn private equity deal with Medline Industries, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
A total of 85 deals worth $37.2bn were announced in June 2021, compared with the 12-month average of 87 deals.
venture financing was the leading category in the month in terms of volume with 57 deals, which accounted for 67.1% of all deals.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
In second place was M&A with 19 deals, followed by private equity with nine transactions, respectively accounting for 22.4% and 10.6% of overall deal activity in the US technology industry during the month.
In terms of value of deals, private equity was the leading deal category in the US medical devices industry with total deals worth $34.42bn, while venture financing and M&A deals totalled $1.63bn and $1.17bn, respectively.
US medical devices industry deals in June 2021: Top deals
The top five medical devices industry deals accounted for 96.1% of the overall value during June 2021.
The combined value of the top five medical devices deals stood at $35.76bn, against the overall value of $37.2bn recorded for the month.
The top five medical devices industry deals of June 2021 tracked by GlobalData were:
1) GIC, Hellman & Friedman, The Blackstone Group and The Carlyle Group’s $34bn private equity deal with Medline Industries
2) The $1bn acquisition of Paramit by Tecan Group
3) Counterpoint Global, Janus Henderson Investors, Logos Global Management, Meritech Capital Partners and T Rowe Price Associates’ $276m venture financing of Element Biosciences
4) The $255m venture financing deal with InSilico Medicine by B Capital Group Management, Baidu Ventures, Bold Capital Partners, CITIC Industrial Investment Fund Management, Deerfield ManagementLP, Eight Roads Ventures, Formic Ventures, Lake Bleu Capital, Lilly Asia ventures, Maison Capital Group, Mirae Asset Capital, Orbimed Advisors, Pavilion Capital Partners, President International Development, Qiming Venture Partners, Sage Partners, Sequoia Capital China, Sinovation Ventures and Warburg Pincus
5) Goldman Sachs Asset Management’s private equity with 4G Clinical for $230m.